UNASSIGNED: Knowledge on how to maintain and expand @entity1358 ( @entity1358 ) in vitro is important to provide a potentially valuable source for kidney replacement therapies. In our present study, we examined the possibility of optimizing @entity1358 maintenance in the "re-aggregate" system. We found that @entity58074 -expressing ( @entity58074 +)- @entity1358 could be maintained in aggregates reconstituted with dispersed cells from E12.5 @entity19 embryonic kidneys for at least up to 21 days in culture. The maintenance of @entity58074 +- @entity1358 required the presence of ureteric bud cells. The number of @entity58074 +- @entity1358 increased by more than 20-fold at day 21, but plateaued after day 14. In an attempt to further sustain @entity1358 proliferation by passage subculture, we found that the new (P1) aggregates reconstituted from the original (P0) aggregates failed to maintain @entity1358 . However, based on the similarity between P1 aggregates and aggregates derived from E15.5 embryonic kidneys, we suspected that the differentiated @entity1358 in P1 aggregates may interfere with @entity1358 maintenance. In support of this notion, we found that preventing @entity1358 differentiation by DAPT, a y-secretase inhibitor that inhibits Notch signaling pathway, was effective to maintain and expand @entity58074 +- @entity1358 in P1 aggregates by up to 65-fold. The @entity58074 +- @entity1358 in P1 aggregates retained their potential to epithelialize upon exposure to Wnt signal. In conclusion, we demonstrated in our present study that the "re-aggregation" system can be useful for in vitro maintenance of @entity1358 when combined with y-secretase inhibitor.

Maintenance of XXXX Nephron Progenitor Cells in Aggregates with Gamma-Secretase Inhibitor.

@entity19 :: ('10090', 'Species') :: ['mouse'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['nephron progenitor cells', 'NPC'] @entity58074 :: ('20472(Tax:10090)', 'Gene') :: ['Six2']
@entity19 :: (10090,Species) :: ['Mouse']
